NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $22.39 +0.31 (+1.40%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get LENZ Therapeutics alerts: Email Address About LENZ Therapeutics Stock (NASDAQ:LENZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$21.72▼$22.4350-Day Range$19.61▼$25.1052-Week Range$14.07▼$29.82Volume534,841 shsAverage Volume129,343 shsMarket Capitalization$81.70 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingBuy Company OverviewLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More… The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.Download my Dividend Calendar here LENZ Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 58th PercentileLENZ Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 476th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.80) per share.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.98% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently decreased by 5.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.98% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently decreased by 5.71%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentLENZ Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.Search Interest1 people have searched for LENZ on MarketBeat in the last 30 days. MarketBeat Follows2 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Stock News HeadlinesLENZ Therapeutics Insiders Up US$178k On US$551.1k InvestmentSeptember 12, 2024 | finance.yahoo.comLENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksAugust 30, 2024 | seekingalpha.comImminent FDA Decision Could End Obesity in America...This drug could end obesity in America... ...and spark a 224,000% sales surge for one tiny micro-cap stock. Channelnomics says it "Could have a greater impact on the world than artificial intelligence."September 20, 2024 | Behind the Markets (Ad)LENZ Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2024 | globenewswire.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024August 26, 2024 | investorplace.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Call TranscriptAugust 19, 2024 | insidermonkey.comLENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBuy Rating Reaffirmed for LENZ Therapeutics Amidst Strong Market Potential and Positive Product DataAugust 16, 2024 | markets.businessinsider.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.20 on January 1st, 2024. Since then, LENZ shares have increased by 38.2% and is now trading at $22.39. View the best growth stocks for 2024 here. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' top institutional investors include Wealth Enhancement Advisory Services LLC (2.28%), Renaissance Technologies LLC (1.65%), Bank of New York Mellon Corp (1.09%) and Dimensional Fund Advisors LP (1.02%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/20/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+59.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.95% Return on Assets-51.59% Debt Debt-to-Equity RatioN/A Current Ratio23.23 Quick Ratio23.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.06 per share Price / Book0.99Miscellaneous Outstanding Shares3,649,000Free Float2,248,000Market Cap$79.91 million OptionableN/A Beta0.39 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:LENZ) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.